DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the CAPLIN POINT LAB LTD. (CAPLIPOINT) share price today?

CAPLIN POINT LAB LTD. (CAPLIPOINT) is trading at ₹2,614.2 on the NSE, down 2.14% on the day. Source: DocStoX.

What is the PE ratio of CAPLIN POINT LAB LTD.?

CAPLIN POINT LAB LTD. has a price-to-earnings (PE) ratio of 31.0 in the Healthcare sector.

What is the market capitalisation of CAPLIN POINT LAB LTD.?

CAPLIN POINT LAB LTD. has a market capitalisation of approximately ₹19,893 crore.

CAPLIN POINT LAB LTD.

CAPLIPOINT·NSE·Healthcare

₹2,614.20▼ -57.30 (-2.14%)

Healthcare · Pharmaceuticals

Debt-free and consistently profitable

NIFTY 500NIFTY SMALLCAP 250

Day₹2576.90

₹2671.90

52W₹1500

₹269993%

Open

₹2671.90

High

₹2671.90

Low

₹2576.90

Prev Close

₹2671.50

Volume

71.1K

VWAP

₹2611.73

Snapshot

Key fundamentals

Market Cap

₹19,893 Cr

P/E Ratio

30.99Fair

P/B Ratio

5.38

EPS

₹84.36

Book Value

₹472.00

ROE

20.60%Strong

ROCE

25.00%Efficient

Dividend Yield

0.15%

Debt / Equity

0.00Low

Face Value

₹2.00

52W High

₹2699.00

52W Low

₹1500.30

Sector

Healthcare

Industry

Pharmaceuticals

Avoid

Narrow moatMedium uncertainty

Fair value estimate

₹752

▼ 71.2%downside

Trading at ₹2,614 — 71% above our estimate

BearFair valueBull

₹639₹752₹947

/100

Business quality — Solid

Growth 68Profitability 89Efficiency 43Valuation 74

Plain English

Our view

Debt-free and consistently profitable
Virtually debt-free balance sheet
Fundamental red flags (Piotroski 1/9)

Strengths

Virtually debt-free balance sheet
Strong returns on equity (21%)
Capital is working hard (ROCE 25%)
Profit growing 20% a year

Risks

Fundamental red flags (Piotroski 1/9)

How we got there

Fair value methods

Residual income

21% ROE fading to 12% over ~10 yrs, on ₹472 book

₹698

Relative P/E

Needs ≥3 peers with P/E

—

Graham floor

Conservative floor: √(22.5 × EPS × book value/share)

₹947

Analyst target

No analyst coverage

—

Blended fair value₹752

What the numbers say

Investment thesis

Bull case

Virtually debt-free balance sheet
Strong returns on equity (21%)
Capital is working hard (ROCE 25%)
Profit growing 20% a year
Promoters hold a controlling stake

Bear case

Fundamental red flags (Piotroski 1/9)

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

31.0Fair

Below 15× is value territory; above 35× prices in strong growth

ROE

20.6%Strong

Above 15% is considered healthy for Indian equities

ROCE

25.0%Efficient

Above 18% means capital is working hard

Debt/Eq

0.00Low

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹19,893 Cr

P/B

5.38

EPS

₹84.36

Div Yield

0.15%

What changed

Recent changes

Foreign investors-0.4% stake last quarter

What matters

News impact

Overview

Valuation

Reasonable

P/E 31.0×

Growth

Steady

+14% rev CAGR

Profitability

Excellent

20.6% ROE

Financial health

Rock solid

D/E 0.00

Momentum

N/A

No technicals

Today

Trading activity

Delivery %54.3%

Turnover₹1856.63L Cr

Trades13,608

VWAP₹2611.73

Face value₹2.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

+14.2%

+15.6%

10Y

+24.8%

Profit

+19.9%

+21.0%

10Y

+30.3%

EPS

+19.4%

+21.4%

10Y

+30.1%

Profile

Pros

Company has reduced debt.
Company is almost debt free.
Company has delivered good profit growth of 21.9% CAGR over last 5 years
Company's median sales growth is 19.9% of last 10 years

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 31 Mar 2026

Foreign investors sold 0.43 pts last quarter. The QoQ column shows each group's change versus the prior quarter.

71%

Promoter

Promoters

70.6%0.00

Public

21.1%+0.33

FII / FPI

6.2%-0.43

DII

2.1%+0.09

Total shareholders

93,896+191 QoQ

Quarterly trend

Ownership over time

Q4 FY26

Promoter70.57%

FII6.15%

DII2.14%

Public21.14%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions

Caplin Point Laboratories Ltd is engaged in the manufacturing and sourcing of APIs, finished formulations, R&D, clinical research with presence in Latin America, Africa, USA and other nations.[1]